METTL3 as a potential therapeutic target in gastric cancer DOI Creative Commons
Zhigang Yu, Yang Yang

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 29, 2024

Gastric cancer (GC) is one of the leading causes cancer-related death worldwide. N6-methyladenosine (m6A) modification most prominent epigenetic eukaryotic mRNAs, and methyltransferase-like 3 (METTL3), a core component methyltransferase complex, catalyzes m6A modification. The results previous studies indicate that expression level METTL3 significantly elevated in gastric tissues cells. In addition, fluctuations levels induced by are closely associated with malignant progression tumors as well poor prognosis patients cancer. this review, we focus on potential mechanism cancer, through our analysis, suggest targeting could be new therapeutic tool for treating GC.

Language: Английский

PROTACs: Novel tools for improving immunotherapy in cancer DOI
Shizhe Li, Ting Chen, Jinxin Liu

et al.

Cancer Letters, Journal Year: 2023, Volume and Issue: 560, P. 216128 - 216128

Published: March 16, 2023

Language: Английский

Citations

25
m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy DOI Creative Commons
Xi Chen,

Yixiao Yuan,

Fan Zhou

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 28, 2025

M6A modification is one of the most common regulatory mechanisms gene expression in eukaryotic cells, influencing processes such as RNA splicing, degradation, stability, and protein translation. Studies have shown that m6A methylation closely associated with tumorigenesis progression, it plays a key role tumor immune responses. participates regulating differentiation maturation well related anti-tumor In microenvironment, can also affect cell recruitment, activation, polarization, thereby promoting or inhibiting proliferation metastasis, reshaping microenvironment. recent years, immunotherapies for tumors, checkpoint inhibitors adoptive immunotherapy, been increasingly applied clinical settings, achieving favorable outcomes. Targeting modifications to modulate system, using small-molecule target dysregulated factors inducing reprogramming, enhance responses strengthen recognition cytotoxicity against cells. represents new direction immunotherapy promising potential. This review discusses on cells explores strategies immunotherapy.

Language: Английский

Citations

1
HNRNPC suppresses tumor immune microenvironment by activating Treg cells promoting the progression of prostate cancer DOI Creative Commons
Yifei Cheng, Lu Li,

Xiyi Wei

et al.

Cancer Science, Journal Year: 2023, Volume and Issue: 114(5), P. 1830 - 1845

Published: Jan. 31, 2023

Immune microenvironment could affect the biological progress in prostate cancer (PCa) through N6 methyl adenosine (m6A) methylation. The purpose of this study was to investigate crosstalk between m6A methylation and immune explore potential biomarkers improve immunotherapeutic response. Firstly, according 11 differentially expressed genes normal tumor samples, PCa patients were divided into subtype 1 (IMS1) IMS2 based on gene profiles extracted from Cancer Genome Atlas (TCGA) database. showed an "cold" phenotype with worse prognoses, HNRNPC identified as biomarker by protein-protein interaction network. Furthermore, bioinformatics analyses vitro experiments, we found that HNRNPC-high a suppressive immune-infiltrating higher infiltration regulatory T (Treg) cells. Finally, cocultured transfected cells peripheral blood mononuclear (PBMC) verified inhibits immunity elevating activation Treg suppression effector CD8 cell. In conclusion, PCa, regulating Activation targeting may be therapeutic option for advanced PCa.

Language: Английский

Citations

20
N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy DOI
Luo Ping, Shiqi Li,

Xinghua Long

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(3), P. 188873 - 188873

Published: Feb. 25, 2023

Language: Английский

Citations

16
N6-methyladenosine RNA modification in stomach carcinoma: Novel insights into mechanisms and implications for diagnosis and treatment DOI
Zhengmao Lu, Zhaojie Lyu, Peixin Dong

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: 1871(5), P. 167793 - 167793

Published: March 14, 2025

Language: Английский

Citations

0
Identification of fatty acid metabolism-related genes in the tumor microenvironment of breast cancer by a development and validation of prognostic index signature DOI Creative Commons

Zhaofeng Ma,

Man Zheng, Pulin Liu

et al.

Hereditas, Journal Year: 2025, Volume and Issue: 162(1)

Published: April 7, 2025

Abstract Background Breast cancer (BRCA) is a malignancy originating in the breast cells, characterized by poor overall survival rate. Post-resection, chemotherapy commonly recommended as primary therapeutic approach; however, its efficacy remains limited. Recent advancements lipidomics and metabolomics have provided new insights into intricate landscape of fatty acid metabolism (FAM) lipidome both health disease. A growing body evidence suggests that dysregulations FAM levels play significant role initiation progression. Despite these advances, precise mechanisms through which mediates anti-cancer effects lobaplatin BRCA remain poorly understood warrant further investigation. Methods GEO TCGA data were classified two types. We aimed to show how FAMGs influence immune function, checkpoints, m6a BRCA. co-expression analysis discovered gene expression strongly connected pyroptosis. The gathered information about mRNAsi, mutations, CNV, clinical features. Results In low-risk group, (OS) longer. GSEA was utilized identify tumor-related pathways. Most FAMG-derived prognostic signatures predominantly modulate immunological oncogenic signaling pathways, including Wnt, neurotrophin, chemokine, calcium cascades. Among genes involved are CEL, WT1, ULBP2. Expression varied well. model, CNVs, single nucleotide polymorphism (SNP), drug sensitivity all pointed gene. Conclusions objective this study validate BRCA-associated can serve indicators provide system while also offering support development metabolism-related molecularly targeted therapeutics. Consequently, their interactions with system, well BRCA, may emerge promising targets.

Language: Английский

Citations

0
Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival DOI Creative Commons
Jing Yang, Zixuan Wu, Xiaoxi Wu

et al.

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Dec. 22, 2022

Stomach adenocarcinoma (STAD) arises from the mutations of stomach cells and has poor overall survival. Chemotherapy is commonly indicated for patients with cancer following surgical resection. The most prevalent alteration that affects growth N6-methyladenosine methylation (m6A), although possible function m6A in STAD prognosis not recognized.The research measured predictive FRGs BLCA samples TCGA GEO datasets. Data on stemness indices (mRNAsi), gene mutations, copy number variations (CNV), tumor mutation burden (TMB), corresponding clinical characteristics were obtained GEO. at 24 was investigated. Lasso regression used to construct prediction model assess prognostic signals STAD. In addition, correlation between m6a immune infiltration discussed using GSVA ssGSEA analysis. Based these genes, GO KEGG analyses performed identify key biological functions pathways.A significant relationship discovered numerous clusters microenvironment, as well three patterns different outcomes. Furthermore, showed significantly associated low-m6Ascore group had a lower immunotherapeutic response than high-m6Ascore group. ICIs therapy more effective higher m6Ascore. Three writers (VIRMA, ZC3H13, METTL3) expression, whereas five authors (METTL14, METTL16, WTAP, RBM15, RBM15B) considerably expression. readers (YTHDC2, YTHDF2, LRPPRC) levels eleven (YTHDC1, YTHDF1, YTHDF3, HNRNPC, FMR1, HNRNPA2B1, IGFBP1, IGFBP2, IGFBP3, RBMX) levels. As can be observed, various types m6 encoders have varied ramifications control.STAD occurrence progression are linked m6A-genes. Corresponding models help forecast patients. m6A-genes cell microenvironment (TME) may serve potential therapeutic targets STAD, which requires further trials. m6a-related signature offers viable alternative predict bladder cancer, show prospective area targeted treatment future.

Language: Английский

Citations

15
METTL14‑mediated RNA methylation in digestive system tumors DOI Creative Commons

Jiexuan Hu,

Haishan Lin, Cong Wang

et al.

International Journal of Molecular Medicine, Journal Year: 2023, Volume and Issue: 52(3)

Published: Aug. 4, 2023

N6‑methyladenosine (m6A) RNA methylation is one of the most common post‑transcriptional modification mechanism in eukaryotes. m6A involved almost all stages mRNA life cycle, specifically regulating its stability, splicing, export and translation. Methyltransferase‑like 14 (METTL14) a particularly important 'writer' that can recognize substrates. METTL14 has been documented to improve activity catalytic efficiency METTL3. However, as individual proteins they also regulate different biological processes. Malignancies digestive system are some malignancies found humans, which typically associated with poor prognoses limited clinical solutions. METTL14‑mediated implicated both potentiation inhibition tumor growth, cell invasion metastasis, addition drug resistance. In present review, research progress regulatory mechanisms were summarized. addition, future directions potential for application examined.

Language: Английский

Citations

8
PCIF1, the only methyltransferase of N6,2-O-dimethyladenosine DOI Creative Commons
Yuting Wu, Xi Pu,

Sihui Wu

et al.

Cancer Cell International, Journal Year: 2023, Volume and Issue: 23(1)

Published: Oct. 1, 2023

Abstract N6-methyladenosine(m6A), is the most abundant post-transcriptional modification of mRNA in biology. When first nucleotide after m7G cap adenosine, it methylated at N6 position to form N6,2-O-dimethyladenosine (m6Am). m6Am a reversible located transcribed nucleotide, which present about 30% cellular mRNAs, thus can have significant impact on gene expression transcriptome. Phosphorylated CTD interaction factor 1(PCIF1), unique and specific methyltransferase m6Am, has been shown affect stability, transcription, translation. Several studies that PCIF1 clearly associated with tumor, viral, endocrine diseases. Moreover, may be related tumor microenvironment, immune cell typing, programmed death protein 1(PD-1) drug resistance. Here, we summarize mechanism involvement modifications, outline modifications diseases involved. We also summarized role checkpoint blockade(ICB) treatment, predicted possibility as biomarker therapeutic target.

Language: Английский

Citations

8
Role of N6‐methyladenosine RNA modification in cancer DOI Creative Commons
Yi Qu, Nannan Gao, Shengwei Zhang

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(9)

Published: Sept. 1, 2024

Abstract N6‐methyladenosine (m6A) is the most abundant modification of RNA in eukaryotic cells. Previous studies have shown that m6A pivotal diverse diseases especially cancer. corelates with initiation, progression, resistance, invasion, and metastasis However, despite these insights, a comprehensive understanding its specific roles mechanisms within complex landscape cancer still elusive. This review begins by outlining key regulatory proteins their posttranslational modifications (PTMs), as well role chromatin accessibility transcriptional activity Additionally, it highlights impact progression modulating programmed cell death affecting tumor microenvironment through various cancer‐associated immune Furthermore, discusses how microorganisms can induce enduring epigenetic changes oncogenic effect microorganism‐associated cancers altering modifications. Last, delves into immunotherapy, encompassing therapy, checkpoint blockade, cytokine adoptive transfer direct targeting regulators. Overall, this clarifies multifaceted explores targeted therapies aimed at manipulating modification, aiming to advance research improve patient outcomes.

Language: Английский

Citations

3